VTIX vs KLRS Comparison

Virtuix Holdings Inc develops technologies for immersive virtual environments, including both simulated and real-world applications. It develops virtual reality hardware and software, including the Omni Pro, an omni-directional treadmill designed to allow users to walk and run in multiple directions inside video games and other virtual worlds. The company operates at the intersection of gaming, fitness, and enterprise virtual reality. It has commercialized three products. The company operates in a single operating segment: the design, development, marketing, and sale of omni-directional treadmills, accessories, and related services to consumer and commercial customers. It derives revenue through a combination of hardware sales and recurring software and service income.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.